Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

Fig. 3

CD38 expression on myeloid, natural killer (NK) and T cells in peripheral blood mononuclear cells (PBMC) from healthy donors and patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). a Quantification of CD38 MFI on CD56+CD16+ NK cells, CD11c+ classical DC, and BDCA2+ plasmacytoid dendritic cells (DC). b Quantification of CD38 MFI on CD45RA+ naïve T cells, CD62LhiCD27hiCCR7+CD45RA central memory T cells (TCM) and CD62LCD45RA effector memory T cell (TEM). c Representative fluorescence-activated cell sorting (FACS) plot of CD38 expression on CD4+CD127lowCD25hi T regulatory cells (Tregs). d Proportion of the CD38bri subset in peripheral Tregs from healthy controls and donors with SLE or RA

Back to article page